Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul>
<li>NetraMark is expanding its capabilities, recently forming a collaboration with Pentara to launch an AI tool to provide insight into participating trial sites that deviate from the overall mean.</li>
<li>This can potentially improve aspects of the trial design, including pre-trial site selection and trial site reporting, among others.</li>
<li>The company expects this tool can help accelerate its growth over time.</li>
</ul>


NetraMark is expanding its capabilities, recently forming a collaboration with Pentara to launch an AI tool to provide insight into participating trial sites that deviate from the overall mean.
This can potentially improve aspects of the trial design, including pre-trial site selection and trial site reporting, among others.
The company expects this tool can help accelerate its growth over time.


<ul>
<li>NetraMark expects its insights potentially could protect millions of R&amp;D dollars, increase drug development success rates, lower costs for drug sponsors &amp; shorten the time to commercialization of new therapies.</li>
<li>Developing &amp; commercializing a new drug takes an avg 10-15 years &amp; costs an avg $2.6B, while failure rates are nearly 90%.</li>
<li>In April 2025, NetraMark entered into a global agreement with CRO Worldwide Clinical Trials &amp; expects additional partnerships with other CROs &amp; pharma companies.</li>
</ul>


NetraMark expects its insights potentially could protect millions of R&amp;D dollars, increase drug development success rates, lower costs for drug sponsors &amp; shorten the time to commercialization of new therapies.
Developing &amp; commercializing a new drug takes an avg 10-15 years &amp; costs an avg $2.6B, while failure rates are nearly 90%.
In April 2025, NetraMark entered into a global agreement with CRO Worldwide Clinical Trials &amp; expects additional partnerships with other CROs &amp; pharma companies.


NetraMark Holdings Inc - Solutions to De-Risk Clinical Research Trials...

NetraMark Holdings Inc. - Solutions to De-Risk Clinical Research Trials...

Canada

NetraMark Holdings Inc. operates as a a software technology company. The Company focuses on improving the understanding of how patients, within and across diseases, relate to each other through the integration of multiple types of data via a unique AI enhancing software package. NetraMark Holdings serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

NetraMark Holdings (AIAI CN)

NetraMark Is Expanding Its Capabilities

NetraMark is expanding its capabilities, recently forming a collaboration with Pentara to launch an AI tool to provide insight into participating...

Zacks Small Cap Research

NetraMark Holdings Inc - Solutions to De-Risk Clinical Research Trials...

In April 2025, NetraMark entered into a global agreement with CRO Worldwide Clinical Trials & expects additional partnerships with other CROs &...

Zacks Small Cap Research

NetraMark Holdings Inc. - Solutions to De-Risk Clinical Research Trials...

In April 2025, NetraMark entered into a global agreement with CRO Worldwide Clinical Trials & expects additional partnerships with other CROs &...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)